Kroatien - kroatiska - HALMED (Agencija za lijekove i medicinske proizvode)

bavarian nordic a/s, philip heymans allé 3, hellerup, danska - virus bjesnoće, soj flury lep (inaktiviran) - prašak i otapalo za otopinu za injekciju u napunjenoj štrcaljki - 1 doza = 1 ml - urbroj: 1 bočica (1,0 ml) nakon rekonstitucije sadrži: virus bjesnoće (inaktivirani, soj flury lep) ≥ 2,5 internacionalne jedinice (iu), proizveden na pročišćenim stanicama pilećih embrija (pcec)

Europeiska unionen - kroatiska - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europeiska unionen - kroatiska - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europeiska unionen - kroatiska - EMA (European Medicines Agency)

sanofi pasteur europe - filamentous haemagglutinin, haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate), hepatitis b surface antigen, pertussis toxoid, poliovirus (inactivated) type 1 (mahoney strain) produced on vero cells, poliovirus (inactivated) type 2 (mef-1 strain) produced on vero cells, poliovirus (inactivated) type 3 (saukett strain) produced on vero cells, tetanus protein, tetanus toxoid adsorbed on aluminium hydroxide, hydrated, diphtheria toxoid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - cjepiva - hexyon (dtap-ipv--hb hib) je indiciran za primarne i booster cijepljenje dojenčadi i male djece od 6 tjedana starosti protiv difterije, tetanusa, protiv pertusisa, hepatitisa b, poliomijelitisa i invazivnih bolesti uzrokovane haemophilus influenzae tip b (hib). korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Europeiska unionen - kroatiska - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp65 virus - immunologicals - mačke - aktivna imunizacija mačaka starijih od 12 tjedana kako bi se spriječila smrtnost zbog zaraze bjesnoće. početak imuniteta: 4 tjedna nakon primarnog cijepljenja. trajanje imuniteta nakon primarne cijepljenja: 1 godina. trajanje imunosti nakon ponovne vakcinacije: 3 godine.

Kroatien - kroatiska - HALMED (Agencija za lijekove i medicinske proizvode)

ever valinject gmbh, oberburgau 3, unterach am attersee, austrija - deksmedetomidinklorid - koncentrat za otopinu za infuziju - 100 mcg/ml - urbroj: jedan ml koncentrata sadrži deksmedetomidinklorid u količini koja odgovara 100 mikrograma deksmedetomidina

Kroatien - kroatiska - HALMED (Agencija za lijekove i medicinske proizvode)

sanofi winthrop industrie, 6 boulevard de l'europe, quetigny, francuska - furosemid - tableta - 40 mg - urbroj: jedna tableta sadrži 40 mg furosemida

Kroatien - kroatiska - HALMED (Agencija za lijekove i medicinske proizvode)

orion corporation, orionintie 1, espoo, finska - sugamadeksnatrij - otopina za injekciju - urbroj: 1 ml otopine sadrži 100 mg sugamadeksa (u obliku sugamadeksnatrija)

Kroatien - kroatiska - HALMED (Agencija za lijekove i medicinske proizvode)

mibe pharmaceuticals d.o.o., zavrtnica 17, zagreb, hrvatska - fusidatna kiselina hemihidrat, betametazonvalerat - krema - 20 mg/g + 1 mg/g - urbroj: 1 g kreme sadrži 20,4 mg fusidatne kiseline 0,5 h2o (ekvivalentno 20 mg fusidatne kiseline) i 1,214 mg betametazonvalerata (ekvivalentno 1 mg betametazona)

Kroatien - kroatiska - HALMED (Agencija za lijekove i medicinske proizvode)

chiesi pharmaceuticals gmbh, gonzagagasse 16/16, beč, austrija - dinatrijev pamidronat - koncentrat za otopinu za infuziju - 15 mg/ml - urbroj: 1 ml koncentrata sadrži 15,0 mg dinatrijevog pamidronata, što odgovara 12,6 mg pamidronatne kiseline